Asthma-COPD overlap is not a homogeneous disorder: further supporting data

Asthma-COPD ovelap (ACO) is an umbrella term that encompasses patients with COPD and eosinophilic inflammation (e-COPD) and smoking asthmatics with non-fully reversible airflow obstruction (SA). We compared the clinical characteristics and the inflammatory profile of e-COPD and SA. Patients classifi...

Descripción completa

Detalles Bibliográficos
Autores: Perez-de-Llano, Luis, García-Cosío, Borja, CHACOS Study Grp
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/9560
Acceso en línea:https://hdl.handle.net/20.500.13003/9560
Access Level:acceso abierto
Palabra clave:Pulmonary Disease, Chronic Obstructive
Cross-Sectional Studies
Middle Aged
Forced Expiratory Volume
Humans
Female
Inflammation Mediators
Male
Aged
Eosinophils
Asthma
Eosinófilos
Anciano
Enfermedad Pulmonar Obstructiva Crónica
Humanos
Mediadores de Inflamación
Estudios Transversales
Femenino
Asma
Volumen Espiratorio Forzado
Persona de Mediana Edad
Masculino
Periostin
COPD
Asthma-COPD overlap
ACO
Descripción
Sumario:Asthma-COPD ovelap (ACO) is an umbrella term that encompasses patients with COPD and eosinophilic inflammation (e-COPD) and smoking asthmatics with non-fully reversible airflow obstruction (SA). We compared the clinical characteristics and the inflammatory profile of e-COPD and SA. Patients classified as e-COPD were older and more often male and showed significantly impaired pulmonary function (likely explained by a heavier smoking habit). On the contrary, SA had more atopic features, more reversibility of airflow obstruction and higher IgE levels. The concentrations of IL-5, IL-13, IL-8, IL-6, TNF-alpha, IL17 in serum were similar between the 2 groups. However, Th2-related biomarkers (periostin, FeNO and blood eosinophils) shower higher median values in e-COPD patients. Our findings reinforce the notion that ACO is a heterogeneous disorder and, as a consequence, it might be unacceptable to offer the same treatment for two related but different conditions.